Avecia is a private biotechnology company focused on the development and manufacture of innovative biotechnology-based medicines. The company has been engaged in the development of innovative bioprocesses for over 30 years and is a leader in the process development and manufacture of microbial-derived biologics. Products currently being worked on include medicines targeted at forms of cancer, heart conditions, stroke, growth and blood disorders.

Company was acquired by Nitto Denko Corp.